Vendor review
Guangzhou Jeep Biotechnology JEEP reviews
Guangzhou Jeep Biotechnology JEEP reviews from 60 independent lab tests (Retatrutide, Tirzepatide and GHK-Cu): grade A, purity and fill accuracy. Is Guangzhou Jeep Biotechnology JEEP legit? See what its vials showed.
What the lab tests show
60 tests on record, newest first. Scores are purity divided by ten.
| Date | Product | Purity | Quantity | Identity | Certificate |
|---|---|---|---|---|---|
| Oct 9, 2026 | Retatrutide | 99.9 % | 29.99 mg of 30 mg (0 %) | Pass | View |
| Sep 29, 2026 | Retatrutide | 99.99 % | 11.2 mg of 10 mg (12 %) | Pass | View |
| Sep 24, 2026 | Retatrutide | 99.9 % | 9.17 mg of 10 mg (-8 %) | Pass | View |
| Sep 23, 2026 | Retatrutide | 99.9 % | 18.2 mg of 20 mg (-9 %) | Pass | View |
| Sep 18, 2026 | Retatrutide | 99.9 % | 60.8 mg of 60 mg (1 %) | Pass | View |
| Sep 16, 2026 | Retatrutide | 30 mg | Fail | View | |
| Sep 15, 2026 | Retatrutide | 99.9 % | 15.1 mg of 20 mg (-25 %) | Pass | View |
| Aug 12, 2026 | Retatrutide | 99.9 % | 34.9 mg of 40 mg (-13 %) | Pass | View |
| Aug 12, 2026 | Retatrutide | 93.8 % | 20.9 mg of 30 mg (-30 %) | Pass | View |
| Aug 9, 2026 | Tesamorelin | 99.7 % | 11.4 mg of 10 mg (14 %) | Pass | View |
| Aug 5, 2026 | Retatrutide | 99.9 % | 26.3 mg of 30 mg (-12 %) | Pass | View |
| Aug 4, 2026 | Retatrutide | 99.3 % | 9.87 mg of 10 mg (-1 %) | Pass | View |
| Aug 4, 2026 | Tirzepatide | 99.9 % | 20 mg of 20 mg (0 %) | Pass | View |
| Aug 3, 2026 | Retatrutide | 30 mg | View | ||
| Aug 2, 2026 | Retatrutide | 99.7 % | 30.8 mg of 30 mg (3 %) | Pass | View |
| Jul 20, 2026 | Retatrutide | 98.6 % | 20.2 mg of 20 mg (1 %) | Pass | View |
| Jul 20, 2026 | Tirzepatide | 99.9 % | 37.8 mg of 40 mg (-6 %) | Pass | View |
| Jul 17, 2026 | Retatrutide | 99.9 % | 10.6 mg of 10 mg (6 %) | Pass | View |
| Jul 13, 2026 | Tesamorelin | 94.8 % | 11.5 mg of 20 mg (-43 %) | Pass | View |
| Jul 13, 2026 | Retatrutide | 99.9 % | 29.4 mg of 30 mg (-2 %) | Pass | View |
| Jul 13, 2026 | Retatrutide | 99.9 % | 27.4 mg of 20 mg (37 %) | Pass | View |
| Jul 13, 2026 | GHK-Cu | 99.8 % | 74.4 mg of 100 mg (-26 %) | Pass | View |
| Jun 16, 2026 | Retatrutide | 99.9 % | 27.4 mg of 30 mg (-9 %) | Pass | View |
| Jun 15, 2026 | Retatrutide | 99.9 % | 9.36 mg of 10 mg (-6 %) | Pass | View |
| May 20, 2026 | Retatrutide | 99.9 % | 32.3 mg of 30 mg (8 %) | Pass | View |
| May 20, 2026 | Tirzepatide | 99.9 % | 58.1 mg of 60 mg (-3 %) | Pass | View |
| May 11, 2026 | Tirzepatide | 99.9 % | 59.7 mg of 60 mg (-1 %) | Pass | View |
| Apr 28, 2026 | Tirzepatide | 99.9 % | 27.2 mg of 30 mg (-9 %) | Pass | View |
| Apr 27, 2026 | Retatrutide | 99.8 % | 31.7 mg of 30 mg (6 %) | Pass | View |
| Apr 23, 2026 | Tirzepatide | 99.8 % | 35.1 mg of 30 mg (17 %) | Pass | View |
| Apr 22, 2026 | Tirzepatide | 30 mg | View | ||
| Apr 21, 2026 | GHK-Cu | 99.6 % | 90.9 mg of 100 mg (-9 %) | Pass | View |
| Apr 21, 2026 | Retatrutide | 99.5 % | 32.4 mg of 30 mg (8 %) | Pass | View |
| Mar 16, 2026 | Retatrutide | 99.9 % | 60.3 mg of 60 mg (0 %) | Pass | View |
| Mar 4, 2026 | Tirzepatide | 98.84 % | 30.7 mg of 30 mg (2 %) | Pass | View |
| Feb 22, 2026 | Retatrutide | 99.9 % | 21.3 mg of 20 mg (7 %) | Pass | View |
| Feb 22, 2026 | Tirzepatide | 99.85 % | 9.65 mg of 10 mg (-3 %) | Pass | View |
| Feb 20, 2026 | Tirzepatide | 99.83 % | 30.9 mg of 30 mg (3 %) | Pass | View |
| Feb 20, 2026 | Ipamorelin | 99.86 % | 5 mg of 5 mg (0 %) | Pass | View |
| Feb 20, 2026 | CJC-1295 | 99.55 % | 5.43 mg of 5 mg (9 %) | Pass | View |
| Feb 18, 2026 | Tesamorelin | 99.9 % | 9.89 mg of 10 mg (-1 %) | Pass | View |
| Feb 18, 2026 | GHK-Cu | 99.9 % | 54 mg of 50 mg (8 %) | Pass | View |
| Feb 16, 2026 | Retatrutide | 99.9 % | 10.2 mg of 10 mg (2 %) | Pass | View |
| Feb 11, 2026 | Tirzepatide | 99.9 % | 39.5 mg of 40 mg (-1 %) | Pass | View |
| Feb 10, 2026 | Tirzepatide | 99.8 % | 32.5 mg of 30 mg (8 %) | Pass | View |
| Jan 19, 2026 | Retatrutide | 99.95 % | 9.03 mg of 10 mg (-10 %) | Pass | View |
| Jan 15, 2026 | Tirzepatide | 99.7 % | 33.6 mg of 30 mg (12 %) | Pass | View |
| Jan 1, 2026 | Tirzepatide | 99.9 % | 34.7 mg of 30 mg (16 %) | Pass | View |
| Dec 30, 2025 | Tirzepatide | 99.95 % | 29.4 mg of 30 mg (-2 %) | Pass | View |
| Dec 29, 2025 | Retatrutide | 99.7 % | 20.4 mg of 20 mg (2 %) | Pass | View |
| Dec 29, 2025 | Retatrutide | 99.7 % | 33.3 mg of 30 mg (11 %) | Pass | View |
| Dec 29, 2025 | Ipamorelin | 99.29 % | 5.23 mg of 5 mg (5 %) | Pass | View |
| Dec 29, 2025 | CJC-1295 | 99.95 % | 4.72 mg of 5 mg (-6 %) | Pass | View |
| Nov 25, 2025 | GHK-Cu | 99.88 % | 55.5 mg of 50 mg (11 %) | Pass | View |
| Nov 25, 2025 | Tesamorelin | 81.92 % | 11.1 mg of 10 mg (11 %) | Pass | View |
| Nov 25, 2025 | CJC-1295 | 84.26 % | 4.22 mg of 5 mg (-16 %) | Pass | View |
| Nov 14, 2025 | Retatrutide | 99.7 % | 5.4 mg of 5 mg (8 %) | Pass | View |
| Nov 14, 2025 | Ipamorelin | 99.9 % | 5.1 mg of 5 mg (2 %) | Pass | View |
| Oct 23, 2025 | GHK-Cu | 99.95 % | 43.8 mg of 50 mg (-12 %) | Pass | View |
| Oct 14, 2025 | Tirzepatide | 99.8 % | 29.5 mg of 30 mg (-2 %) | Pass | View |
What Guangzhou Jeep Biotechnology JEEP sells
Current listings from the vendor's own store, by peptide.
About Guangzhou Jeep Biotechnology JEEP
Finnrick has tested 60 samples from Guangzhou Jeep Biotechnology JEEP across 6 products.